ResMed Inc. (NYSE:RMD) Director Richard Sulpizio sold 24,390 shares of the firm’s stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of $73.85, for a total value of $1,801,201.50. Following the completion of the sale, the director now owns 28,819 shares in the company, valued at $2,128,283.15. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Richard Sulpizio also recently made the following trade(s):

  • On Thursday, June 22nd, Richard Sulpizio sold 65,887 shares of ResMed stock. The shares were sold at an average price of $77.82, for a total value of $5,127,326.34.

Shares of ResMed Inc. (NYSE RMD) traded down 0.08% during trading on Friday, hitting $72.56. The stock had a trading volume of 421,738 shares. The stock’s 50 day moving average is $76.66 and its 200 day moving average is $72.21. ResMed Inc. has a 52 week low of $56.59 and a 52 week high of $79.63. The stock has a market capitalization of $10.32 billion, a price-to-earnings ratio of 30.23 and a beta of 0.83.

ResMed (NYSE:RMD) last posted its quarterly earnings data on Tuesday, August 1st. The medical equipment provider reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.75 by $0.02. ResMed had a return on equity of 21.99% and a net margin of 16.56%. The firm had revenue of $556.69 million for the quarter, compared to the consensus estimate of $557.68 million. During the same quarter in the prior year, the business earned $0.74 EPS. The business’s revenue for the quarter was up 7.3% compared to the same quarter last year. On average, equities research analysts expect that ResMed Inc. will post $3.03 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 21st. Shareholders of record on Thursday, August 17th will be issued a dividend of $0.35 per share. This is an increase from ResMed’s previous quarterly dividend of $0.33. The ex-dividend date is Tuesday, August 15th. This represents a $1.40 annualized dividend and a yield of 1.93%. ResMed’s dividend payout ratio is currently 54.77%.

COPYRIGHT VIOLATION NOTICE: “Richard Sulpizio Sells 24,390 Shares of ResMed Inc. (RMD) Stock” was reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at https://www.americanbankingnews.com/2017/08/11/richard-sulpizio-sells-24390-shares-of-resmed-inc-rmd-stock.html.

Several brokerages have recently issued reports on RMD. Zacks Investment Research upgraded ResMed from a “sell” rating to a “hold” rating in a research report on Tuesday, June 20th. Credit Suisse Group cut ResMed from an “outperform” rating to a “neutral” rating in a research report on Wednesday, August 2nd. BMO Capital Markets lifted their price target on ResMed from $61.00 to $70.00 and gave the company a “market perform” rating in a research report on Wednesday, August 2nd. Citigroup Inc. upgraded ResMed from a “neutral” rating to a “buy” rating in a research report on Wednesday, August 2nd. Finally, Needham & Company LLC reiterated a “sell” rating on shares of ResMed in a research report on Wednesday, August 2nd. Four analysts have rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the stock. ResMed has a consensus rating of “Hold” and a consensus target price of $65.63.

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. boosted its stake in shares of ResMed by 5,439.8% in the first quarter. BlackRock Inc. now owns 13,335,138 shares of the medical equipment provider’s stock valued at $959,731,000 after buying an additional 13,094,421 shares during the last quarter. FMR LLC boosted its stake in shares of ResMed by 38.2% in the second quarter. FMR LLC now owns 5,542,582 shares of the medical equipment provider’s stock valued at $431,601,000 after buying an additional 1,531,772 shares during the last quarter. Morgan Stanley boosted its stake in shares of ResMed by 69.1% in the first quarter. Morgan Stanley now owns 1,344,234 shares of the medical equipment provider’s stock valued at $96,744,000 after buying an additional 549,279 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of ResMed by 4.6% in the first quarter. Vanguard Group Inc. now owns 11,535,707 shares of the medical equipment provider’s stock valued at $830,225,000 after buying an additional 508,392 shares during the last quarter. Finally, First Trust Advisors LP boosted its stake in shares of ResMed by 191.8% in the second quarter. First Trust Advisors LP now owns 350,012 shares of the medical equipment provider’s stock valued at $27,255,000 after buying an additional 230,056 shares during the last quarter. 60.68% of the stock is currently owned by hedge funds and other institutional investors.

About ResMed

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Insider Buying and Selling by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.